Replies to post #22714 on Abattis Bioceuticals Corp. (ATTBF)

[UglyAmerican]

Abattis publically stated on twitter that Biocell has new products being launched in late January 2015. Of course, at this time, no one knows what those products are. With what being said, I think it is important for current and prospective share holders to be aware of the following information regarging Biocell:

Biocell Labs has a lease on a 13 million dollar facility. Biocell has flash-freeze technology which will be able to extract CBDs without damaging the purity of the product. Biocell has applied for license for the Purgenesis facility.

http://www.purgenesis.com/

BioCell is a wholly-owned subsidiary of Abattis Bioceuticals Corp., and is in the businesses of biotechnology with a focus on the research, licensing and marketing of high quality botanical products, vitamins and mineral supplements. PurGenesis is a private Quebec-based botanical pharmaceutical company. BioCell has applied to Health Canada for a Research & Development License under exemption 56 to produce cannabis with the intent to commercialize (the “License”).

Under the lease agreement, PurGenesis will lease to BioCell approximately 1,000 to 1,500 square feet of lab space that meets the requirements of Health Canada’s Current Good Manufacturing Practices (GMP) Guidelines (the “PurGenesis Facility.”) The PurGenesis Facility will be located at PurGenesis’ premises located at 360 Des Entrepreneurs Montmagny, QC G5V 4T1. PurGenesis will provide the services of two of its employees, to act as the Project Manager and the Production Manager, and who will allocate time to perform work in the PurGenesis Facility on behalf of BioCell.

PurGenesis and BioCell will consider entering into a joint venture agreement that would be owned by both parties in equal portion that would own its own MMPR and LP Licenses, lease the premises and conduct research and manufacturing. Under the joint venture, PurGenesis would provide it proprietary extraction technology, as well as all its pharmaceutical development expertise to products emerging from the R&D activities. Biocell would provide other technologies. The anticipated joint venture would provide patients with a pharmaceutical grade Cannabis and its derivatives.